柘中股份(002346.SZ)控股股東4000萬股質押延期購回
格隆匯3月11日丨柘中股份(002346.SZ)公佈,公司近日接到公司控股股東上海康峯投資管理有限公司關於其持有的公司合計4000萬股股權質押延期購回的通知,延期後的質押到期日為2021年3月8日。
公司控股股東未來半年內到期的股份質押累計數量為1.38億股,佔其持有公司股份的50.02%,佔公司總股本的31.27%,融資餘額為5億元;未來一年內(含半年內到期)合計到期的質押股份累計數量為1.78億股,佔其持有公司股份的64.51%,佔公司總股本的40.33%,對應融資餘額為6.5億元。公司控股股東還款資金來源主要來自於其經營所得、自籌資金,具備相應的資金償還能力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.